In June 2018, Evotec and Sanofi signed an agreement to combat infectious diseases. As part of the agreement, Evotec integrated Sanofi’s infectious disease unit in Lyon into its organization and in-licensed the majority of Sanofi’s infectious disease research portfolio and initiatives comprising a series of anti-microbial and anti-viral compounds. 

The anti-Chikungunya monoclonal antibody program EVT894 is Evotec’s most advanced anti-viral program having entered clinical phase testing in December 2020. The program is a collaboration with many international partners aimed at providing a cure and prophylaxis for a
disease for which currently no treatment exists.

Download the Drug Discovery Insights to learn more about EVT894 and Evotec's Approach to Fighting Chikungunya.